Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16,837 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular testing in lung cancer: the time is now.
Cheng H, Xu X, Costa DB, Powell CA, Halmos B. Cheng H, et al. Curr Oncol Rep. 2010 Sep;12(5):335-48. doi: 10.1007/s11912-010-0118-z. Curr Oncol Rep. 2010. PMID: 20623207 Review.
Cell cycle inhibitors for the treatment of NSCLC.
Shcherba M, Liang Y, Fernandes D, Perez-Soler R, Cheng H. Shcherba M, et al. Among authors: cheng h. Expert Opin Pharmacother. 2014 May;15(7):991-1004. doi: 10.1517/14656566.2014.902935. Epub 2014 Mar 25. Expert Opin Pharmacother. 2014. PMID: 24666387 Review.
Emerging drugs for squamous cell lung cancer.
Cheng H, Shcherba M, Kandavelou K, Liang Y, Liu H, Perez-Soler R. Cheng H, et al. Expert Opin Emerg Drugs. 2015 Mar;20(1):149-60. doi: 10.1517/14728214.2015.1001365. Epub 2015 Jan 5. Expert Opin Emerg Drugs. 2015. PMID: 25557559 Review.
Emerging treatment for advanced lung cancer with EGFR mutation.
Inal C, Yilmaz E, Piperdi B, Perez-Soler R, Cheng H. Inal C, et al. Among authors: cheng h. Expert Opin Emerg Drugs. 2015;20(4):597-612. doi: 10.1517/14728214.2015.1058778. Epub 2015 Jul 8. Expert Opin Emerg Drugs. 2015. PMID: 26153235 Review.
RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.
Cheng H, Zou Y, Ross JS, Wang K, Liu X, Halmos B, Ali SM, Liu H, Verma A, Montagna C, Chachoua A, Goel S, Schwartz EL, Zhu C, Shan J, Yu Y, Gritsman K, Yelensky R, Lipson D, Otto G, Hawryluk M, Stephens PJ, Miller VA, Piperdi B, Perez-Soler R. Cheng H, et al. Cancer Discov. 2015 Dec;5(12):1262-70. doi: 10.1158/2159-8290.CD-14-0971. Epub 2015 Sep 14. Cancer Discov. 2015. PMID: 26370156 Free PMC article.
16,837 results
You have reached the last available page of results. Please see the User Guide for more information.